Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of aspergillus infections

Natalie K. Boyd, Cindy L. Zoellner, Mark A. Swancutt, Kavita P. Bhavan

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Voriconazole is the preferred antifungal agent for Aspergillus infections. Therapeutic drug monitoring is recommended to achieve target concentrations and prevent toxicity. However, variable pharmacokinetics, cytochrome P450 polymorphisms, and extensive drug-drug interactions can contribute to subtherapeutic concentrations. We report a voriconazole "boosting" effect of omeprazole to achieve target concentrations for the treatment of Aspergillus in a patient who had persistently subtherapeutic trough concentrations.

Original languageEnglish (US)
Pages (from-to)6001-6002
Number of pages2
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number11
DOIs
StatePublished - Nov 2012

Fingerprint

Omeprazole
Aspergillus
Drug Monitoring
Antifungal Agents
Infection
Drug Interactions
Cytochrome P-450 Enzyme System
Pharmacokinetics
Therapeutics
Pharmaceutical Preparations
Voriconazole

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of aspergillus infections. / Boyd, Natalie K.; Zoellner, Cindy L.; Swancutt, Mark A.; Bhavan, Kavita P.

In: Antimicrobial Agents and Chemotherapy, Vol. 56, No. 11, 11.2012, p. 6001-6002.

Research output: Contribution to journalArticle

@article{afb30124e8684f709042f96371852e55,
title = "Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of aspergillus infections",
abstract = "Voriconazole is the preferred antifungal agent for Aspergillus infections. Therapeutic drug monitoring is recommended to achieve target concentrations and prevent toxicity. However, variable pharmacokinetics, cytochrome P450 polymorphisms, and extensive drug-drug interactions can contribute to subtherapeutic concentrations. We report a voriconazole {"}boosting{"} effect of omeprazole to achieve target concentrations for the treatment of Aspergillus in a patient who had persistently subtherapeutic trough concentrations.",
author = "Boyd, {Natalie K.} and Zoellner, {Cindy L.} and Swancutt, {Mark A.} and Bhavan, {Kavita P.}",
year = "2012",
month = "11",
doi = "10.1128/AAC.00700-12",
language = "English (US)",
volume = "56",
pages = "6001--6002",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of aspergillus infections

AU - Boyd, Natalie K.

AU - Zoellner, Cindy L.

AU - Swancutt, Mark A.

AU - Bhavan, Kavita P.

PY - 2012/11

Y1 - 2012/11

N2 - Voriconazole is the preferred antifungal agent for Aspergillus infections. Therapeutic drug monitoring is recommended to achieve target concentrations and prevent toxicity. However, variable pharmacokinetics, cytochrome P450 polymorphisms, and extensive drug-drug interactions can contribute to subtherapeutic concentrations. We report a voriconazole "boosting" effect of omeprazole to achieve target concentrations for the treatment of Aspergillus in a patient who had persistently subtherapeutic trough concentrations.

AB - Voriconazole is the preferred antifungal agent for Aspergillus infections. Therapeutic drug monitoring is recommended to achieve target concentrations and prevent toxicity. However, variable pharmacokinetics, cytochrome P450 polymorphisms, and extensive drug-drug interactions can contribute to subtherapeutic concentrations. We report a voriconazole "boosting" effect of omeprazole to achieve target concentrations for the treatment of Aspergillus in a patient who had persistently subtherapeutic trough concentrations.

UR - http://www.scopus.com/inward/record.url?scp=84868014757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868014757&partnerID=8YFLogxK

U2 - 10.1128/AAC.00700-12

DO - 10.1128/AAC.00700-12

M3 - Article

VL - 56

SP - 6001

EP - 6002

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -